A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Conditions
Breast Cancer · TNBC - Triple-Negative Breast Cancer · HER2-negative Breast Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Arizona Oncology Associates, Tucson, Arizona, United States
Valkyrie Clinical Trials, Los Angeles, California, United States
Contact: Principal Investigator (David Berz, MD)FOMAT Medical Research, Oxnard, California, United States
Contact: Study coordinator (Kelly Schlingensiepen) · kschlingensiepen@fomatmedical.com · 805-483-1185Contact: Principal Investigator (Nawazish Khan, MD)AP Medical Research, Miami, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Contact: Principal Investigator (Tracey O'Connor, MD)Northwest Cancer Center, Dyer, Indiana, United States
Contact: Principal Investigator (Shruti Singh, MD)University of Maryland Medical Center (UMMC), Baltimore, Maryland, United States
Contact: Principal Investigator (Katherine Tkaczuk, MD)Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Contact: Principal Investigator (Mridula George, MD)Clinical Research Alliance, Westbury, New York, United States
Gabrail Cancer Center Research, Canton, Ohio, United States
Contact: Principal Investigator (Nashat Gabrail, MD)SCRI Oncology Partners, Nashville, Tennessee, United States
Contact: Principal Investigator (Denise Yardley, MD)Texas Oncology PA (Austin), Austin, Texas, United States
Texas Oncology PA (San Antonio), San Antonio, Texas, United States